Working... Menu

Prospective Prolaris Value and Efficacy (P-PROVE)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT03152448
Recruitment Status : Recruiting
First Posted : May 15, 2017
Last Update Posted : August 6, 2018
VA Salt Lake City Health Care System
Information provided by (Responsible Party):
Myriad Genetic Laboratories, Inc.

Brief Summary:
This is a prospective study to measure the impact on first-line therapy of genomic testing of biopsy tissue from recently diagnosed treatment-naïve patients with early stage localized prostate cancer.

Condition or disease Intervention/treatment
Prostate Cancer Behavioral: Prolaris

Detailed Description:

This is a prospective study to measure the impact on first-line therapy of genomic testing of biopsy tissue from recently diagnosed treatment-naïve patients with early stage localized prostate cancer. Multiple individual VAMC sites will participate in PART 1 of the study. During PART 1 of the study, a three-part questionnaire will be completed to evaluate the PRE-Prolaris test treatment plan, the POST-Prolaris test treatment plan, and the ACTUAL treatment option. Using PRE-Prolaris Test Questionnaire #1 the physician will record the recommendation for first-line therapy based on standard clinical-pathological parameters (PSA, Gleason score, clinical stage and percent positive cores). The likelihood of recommending a non-interventional therapy approach will also be recorded using a 10-point ordinal scale. A sample of the biopsy tissue will then be tested using the Prolaris® genomic test and a relative cancer aggressiveness score will be shared with the physician. After reviewing and considering the results of the genomic testing and after patient consultation, the physician will complete POST-Prolaris Questionnaire #2 documenting the planned treatment ( interventional treatment or non-interventional). Approximately 6 months from the date of the test results, ACTUAL Treatment Questionnaire #3 will be completed to document the actual treatment administered.

PART 2 of this study is a prospective evaluation of the prognostic utility of Prolaris® testing of prostate biopsy samples obtained from men who participate in PART 1of the study and who undergo radical prostatectomy or radiation therapy or who are managed with WW or AS. The central VAMC site will be responsible for PART 2; individual VAMC sites will not participate in this part of the study. Patients will be followed using medical record review every 6 months for objective progression (BCR, radiographic or radionuclide evidence of metastases or disease specific mortality) through 5 years.

Layout table for study information
Study Type : Observational [Patient Registry]
Estimated Enrollment : 1500 participants
Observational Model: Cohort
Time Perspective: Prospective
Target Follow-Up Duration: 5 Years
Official Title: Two-Part Prospective Study to Measure Impact of Prolaris® Testing Added to Treatment Decision Following Biopsy in Newly Diagnosed Prostate Cancer Patients to Measure Prediction of Progression/Recurrence in Men Treated at VAMC
Actual Study Start Date : September 1, 2015
Estimated Primary Completion Date : January 2024
Estimated Study Completion Date : January 2024

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Prostate Cancer

Group/Cohort Intervention/treatment
Early Stage Prostate Cancer
Recently diagnosed treatment-naïve patients with early stage localized prostate cancer
Behavioral: Prolaris
Series of three questionnaires to capture treatment decisions based upon standard clinical-pathological information with the addition of Prolaris genomic testing result
Other Name: RNA expression signature based on a set of cell cycle progression (CCP) genes

Primary Outcome Measures :
  1. Impact of Prolaris on magnitude of change between pre-Prolaris treatment selection and the post-Prolaris treatment plan following consultation with the patient [ Time Frame: 3 months ]
    comparison of percentage change from the pre-Prolaris treatment option versus the post-Prolaris treatment plan

  2. Impact of Prolaris on magnitude of change between physician likelihood of recommending non-interventional therapy and the likelihood following the genomic test results [ Time Frame: 3 months ]
    mean change in the physician's likelihood of recommending watchful waiting or active surveillance post-genomic testing compared to pre-genomic testing

Other Outcome Measures:
  1. Prolaris prediction of who benefits from the addition of hormone therapy to contemporary radiation therapy [ Time Frame: 5 years ]
    either biochemical or objective recurrences of disease following definitive therapy with curative intent in men treated with radiation who did or did not receive adjuvant ADT

  2. Comparison of prognostic utility of prospective Prolaris testing of prostate biopsy samples to other clinical pathological parameters with respect to disease progression [ Time Frame: 5 years ]
    either biochemical or objective recurrences of disease following definitive therapy with curative intent in men treated with radical prostatectomy or radiation

  3. Association of Prolaris score with progression to active intervention when initially managed with AS or WW [ Time Frame: 5 years ]
    Progression to interventional therapy in men initially managed with AS or WW

  4. Prognostic utility of Prolaris testing compared to other clinical pathological parameters with respect to disease progression in men who were Gleason score <7 on initial biopsy [ Time Frame: 5 years ]
    biochemical or objective recurrence of disease in men who were Gleason score <7

Biospecimen Retention:   Samples With DNA
Formalin-fixed paraffin-embedded (FFPE) tissue from blocks or slides of prostatic adenocarcinoma biopsies

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Newly diagnosed, clinically localized treatment naïve prostate cancer patients in the US clinical setting

Inclusion Criteria:

  • Newly diagnosed (<= 6 months), untreated patients with histologically proven adenocarcinoma of the prostate
  • Final treatment decision has not been made (that is all treatment options are feasible and none have been ruled out due to comorbidities at study entry)
  • Clinically localized (no evidence on clinical or imaging studies of advanced disease)
  • No hormonal therapy for treatment of prostate cancer including LHRH agonist or antagonist, anti-androgen, estrogens or exogenous androgens when applicable (use of 5-alpha reductase inhibitors is acceptable)
  • Sufficient amount of tissue remains from biopsy to perform genomic testing
  • Life expectance of a minimum of 10 years
  • Men who completed PART 1 and were treated with radical prostatectomy (including robotic, laparoscopic, open retropubic or perineal) or receive radiation therapy or were placed on AS or WW.

Exclusion Criteria:

  • Men with clinical node positive or metastatic disease
  • Men with a known baseline total serum testosterone level of <100 ng/dL prior to radiation or hormone therapy (men with unknown baseline testosterone levels will not be excluded)
  • Men who previously received pelvic radiotherapy for another malignancy
  • Non adenocarcinoma prostate cancer histologies

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03152448

Layout table for location contacts
Contact: Todd Cohen, MD

Layout table for location information
United States, California
VA San Diego Healthcare System Recruiting
San Diego, California, United States, 92161
Contact: Kyoko Sakamoto, MD    858-642-3407      
Principal Investigator: Kyoko Sakamoto, MD         
United States, Connecticut
VA Connecticut Healthcare System Recruiting
West Haven, Connecticut, United States, 06516
Contact: Preston Sprenkle, MD    203-932-5711 ext 5871      
Principal Investigator: Preston Sprenkle, MD         
United States, Florida
James A. Haley Veterans' Hospital Recruiting
Tampa, Florida, United States, 33612
Contact: Cesar Ercole, MD   
Principal Investigator: Cesar Ercole, MD         
United States, Kansas
Kansas City VAMC Recruiting
Kansas City, Kansas, United States, 64128
Contact: Sharad Mathur, MD   
Principal Investigator: Sharad Mathur, MD         
United States, Louisiana
Southeast Louisiana Veterans Healtchare System Recruiting
New Orleans, Louisiana, United States, 70112
Contact: Jonathan Silberstein, MD    504-988-0768      
Principal Investigator: Jonathan Silberstein, MD         
United States, Minnesota
Minneapolis VA Healthcare System Recruiting
Minneapolis, Minnesota, United States, 55417
Contact: Michael Risk, MD   
Principal Investigator: Michael Risk, MD         
United States, Missouri
VA St. Louis Healthcare System Recruiting
Saint Louis, Missouri, United States, 63106
Contact: Ralph Torrence, MD   
Principal Investigator: Ralph Torrence, MD         
United States, New York
James J. Peters VA Recruiting
Bronx, New York, United States, 10468
Contact: Christopher Anderson, MD   
Principal Investigator: Christopher Anderson, MD         
United States, Oklahoma
Oklahoma City Veteran's Hospital Recruiting
Oklahoma City, Oklahoma, United States, 73104
Contact: Felicia Kiplinger, BA    405-271-6900   
Principal Investigator: Kelly Stratton, MD         
United States, South Carolina
Ralph H. Johnson VAMC Recruiting
Charleston, South Carolina, United States, 29401
Contact: Stephen J. Savage, MD    843-792-5787      
Principal Investigator: Stephen J. Savage, MD         
United States, Texas
Michael E. DeBakey VAMC Recruiting
Houston, Texas, United States, 77030
Contact: Jeffrey A. Jones, MD    713-798-4001      
Principal Investigator: Jeffrey A. Jones, MD         
United States, Utah
Salt Lake City VA Medical Center Recruiting
Salt Lake City, Utah, United States, 84148
Contact: William Lowrance, MD, MPH    801-587-4282      
Principal Investigator: William T. Lowrance, MD, MPH         
Sponsors and Collaborators
Myriad Genetic Laboratories, Inc.
VA Salt Lake City Health Care System

Additional Information:

Layout table for additonal information
Responsible Party: Myriad Genetic Laboratories, Inc. Identifier: NCT03152448     History of Changes
Other Study ID Numbers: URO-005
First Posted: May 15, 2017    Key Record Dates
Last Update Posted: August 6, 2018
Last Verified: August 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description: Results of Prolaris testing to be shared with provider and patient per commercial process; study results to be presented in a pier reviewed publication in aggregate form only (no individual participant data to be shared through publications or abstracts)

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Keywords provided by Myriad Genetic Laboratories, Inc.:
Prostate Cancer

Additional relevant MeSH terms:
Layout table for MeSH terms
Prostatic Neoplasms
Genital Neoplasms, Male
Urogenital Neoplasms
Neoplasms by Site
Genital Diseases, Male
Prostatic Diseases